The BHFS Study (Better, Harder, Faster, Stronger): Does Neoadjuvant Chemotherapy Improve Fitness for Surgery?
The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.
• Ability to understand and willingness to sign an IRB-approved informed consent.
• Age \> 55 years at the time of enrollment.
• Newly diagnosed suspected ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype, FIGO Stage II-IV, per enrolling investigator, or newly diagnosed suspected endometrial carcinoma of any histologic subtype, FIGO Stage II-IV, per enrolling investigator.
• Planned for 3 or 4 cycles of NACT, with interval cytoreductive surgery planned thereafter.
• Ability to read, understand, and write the English language.
• As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.